Extended Data Fig. 2. Modularity of SABR-IIs.
A. Schematic (color coded by cell type) for corresponding co-incubation assays demonstrating SABR-IIs in both human (Jurkat) and murine (5KC) cell lines. B. OT-II TCR-expressing Jurkat cells against NFAT-GFP-Jurkats expressing the I-Ab-OVA SABR (left) and OT-II expressing 5KC cells against 5KC cells expressing the I-Ab-OVA SABR (right). Bars represent means from two biological replicates (dots). C. Schematic for corresponding co-incubation assays in NFAT-GFP-Jurkat cells demonstrating SABR-IIs with CD28-CD3z or CD79A and CD79B signaling domains. D. Representative flow plots (left) of OT-II TCR Jurkats co-incubated against NFAT-GFP-Jurkats expressing SABR-IIs with either CD28-CD3z(top) or CD79A and CD79B signaling domains. GFP expression was quantified after 24 hr co-incubation (right) with bars depicting the mean and s.d. (error bars) from 3 biological replicates (dots). E. C. Schematic for corresponding co-incubation assays in Daudi Cells demonstrating SABR-IIs with CD28-CD3z or CD79A and CD79B signaling domains. F. Representative dot plots (left) of Bdc2.5 TCR Jurkats co-incubated against Daudi cells expressing SABR-IIs with either CD28-CD3ζ or CD79A and CD79B signaling domains. The percentage of SABR-II+ Daudi cells expressing FAS was quantified by flow cytometry after 72 hr with bars depicting the mean and s.d. (error bars) from 3 biological replicates (dots).